press release
October 27, 2022 – Comtech CMTL announced today that the Company received over $50.0 million in additional financing during the first quarter of fiscal...
Hi, what are you looking for?
October 27, 2022 – Comtech CMTL announced today that the Company received over $50.0 million in additional financing during the first quarter of fiscal...
#Streamline #Health #Announces #Strategic #Alignment The Company closed the previously announced registered direct offering of common stock for gross proceeds of approximately $8.3 million;...
Spine Center Atlanta partners with Ospitek Inc. to improve the patient experience and empower care teams through the launch of Ospitek’s proprietary live visualization...
#Psychedelic #Drugs #Market #Projected #Grow #magnificent Pune, Oct. 27, 2022 (GLOBE NEWSWIRE) — “Psychedelic Drugs Market” Insights 2022 By Types, Applications, Regions and Forecast...
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. ONCTa clinical-stage biopharmaceutical company focused on developing novel oncology therapies, announced today that...
#VIP #Security #Services #Market #Projected #Grow Pune, Oct. 27, 2022 (GLOBE NEWSWIRE) — “VIP Security Services Market” Insights 2022 By Types, Applications, Regions and...
Establishment of America’s Premier Marine Transportation Company Devall Towing (Devall) and Southern Towing Company (STC) announced today that they will fully integrate the operations...
#Vyant #Bio #Announces #Participation #CDKL5 #Forum Platform and Poster Presentations on Vyant Bio’s Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder...
DUBAI, UAE, Oct. 27, 2022 (GLOBE NEWSWIRE) — QUICKLY is a next-generation, rewards-based Web3 social media application that introduces a new ecosystem that merges...
#SNAPY #launches #snap #earn #feature #earn DUBAI, UAE, Oct. 27, 2022 (GLOBE NEWSWIRE) — SNAPY is a next-generation Web3, reward-based social media application that...
Clovis Oncology, Inc. CLVS today announced the presentation of data from the Phase 3 TRITON3 study in men with metastatic castration-resistant prostate cancer harboring...